Efmody

RSS

hydrocortisone

Authorised
This medicine is authorised for use in the European Union.

Overview

Efmody is a medicine used to treat an inherited condition called congenital adrenal hyperplasia (CAH) in patients 12 years old and above.

CAH is rare, and Efmody was designated as an ‘orphan medicine’ (a medicine used in rare diseases) on 27 July 2005. Further information on the orphan designation can be found here.

Efmody contains the active substance hydrocortisone and is a ‘hybrid medicine’. This means that it is similar to a ‘reference medicine’ containing the same active substance, but Efmody has a different use and is available in different strengths as capsules formulated to release the active substance over a prolonged period. The reference medicine for Efmody capsules is Hydrocortone tablets.

This EPAR was last updated on 06/07/2021

Authorisation details

Product details
Name
Efmody
Agency product number
EMEA/H/C/005105
Active substance
hydrocortisone
International non-proprietary name (INN) or common name
hydrocortisone
Therapeutic area (MeSH)
Adrenal Hyperplasia, Congenital
Anatomical therapeutic chemical (ATC) code
H02AB09
Publication details
Marketing-authorisation holder
Diurnal Europe B.V.
Revision
1
Date of issue of marketing authorisation valid throughout the European Union
27/05/2021

Product information

08/06/2021 Efmody - EMEA/H/C/005105 - IAIN/0001/G

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Corticosteroids for systemic use

Therapeutic indication

Treatment of congenital adrenal hyperplasia (CAH) in adolescents aged 12 years and over and adults.

Assessment history

How useful was this page?

Add your rating
Average
1 rating